The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review

Lumateperone (also known as ITI-007 or ITI-722) represents a novel second-generation medication characterized by a favorable safety and tolerability profile. This is attributed to its notable selectivity for D2 receptors within specific regions of the brain. The U.S. Food and Drug Administration (FD...

Full description

Saved in:
Bibliographic Details
Published in:Brain sciences 2023-11, Vol.13 (12), p.1641
Main Authors: Longo, Giulio, Cicolini, Angelica, Orsolini, Laura, Volpe, Umberto
Format: Article
Language:English
Subjects:
Alzheimer's disease
Antipsychotics
Cognitive ability
Dementia disorders
Depression, Mental
Dopamine
Drug approval
Drug dosages
Drug therapy
FDA approval
ITI-007
ITI-722
Kinases
Lithium
lumateperone
Mental disorders
Metabolites
Neurodegenerative diseases
Neurophysiology
Neurosciences
novel antipsychotics
Oral administration
Permeability
Phosphorylation
Psychotropic drugs
Safety
Schizophrenia
Serotonin
Sleep disorders
Urine
Valproic acid
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!